In Vitro Evidence for the Efficacy of Manuka Honey and Its Components Against the Major Human Pathogenic Sporothrix Species
<b>Background/Objectives</b>: While various clinical manifestations occur in sporotrichosis, cutaneous forms predominate. The recommended sporotrichosis treatment is itraconazole, an antifungal with certain restrictions. In recent years, the observation of reduced treatment effectiveness in some patients has arisen, possibly due to <i>Sporothrix</i> spp. resistance mechanisms. Consequently, there is a growing need for alternative therapeutic approaches. This study investigates the antifungal activity of manuka honey (MH) against pathogenic species of the genus <i>Sporothrix</i>. <b>Methods</b>: In this study, we assessed MH antifungal efficacy across concentrations ranging from 5% to 40% against 26 <i>Sporothrix</i> spp. isolates. In addition, its components were evaluated through chromatography and other in vitro techniques. <b>Results</b>: Minimum inhibitory concentrations of MH were found to be 15-40%, 10-15%, and 5-10% for <i>Sporothrix brasiliensis</i>, <i>Sporothrix schenckii</i>, and <i>Sporothrix globosa</i>, respectively. Purified methylglyoxal did not hinder <i>Sporothrix</i> growth. The MH antifungal potential was compromised through treatment with catalase or filtration through a 0.22 µm cellulose membrane. Chromatographic analysis of the volatile organic compounds (VOCs) present in MH identified 40 VOCs, including carbonyl compounds, alcohols, esters, aromatic hydrocarbons, heterocyclic compounds, terpenoids, and carboxylic acids. Additionally, two phenolic compounds were identified as potential markers for the authentication of MH, along with a disaccharide that may contribute to its antifungal activity. <b>Conclusions</b>: MH has demonstrated biological activity against the most significant <i>Sporothrix</i> species with pathogenic impact on humans. This suggests its consideration in future research endeavors focused on novel topical treatments for cutaneous sporotrichosis in both human and animal subjects.
Authors
- Joshua Daniel Nosanchuk (ORCID: https://orcid.org/0000-0001-9905-5754)
- Ana Cláudia F. Amaral (ORCID: https://orcid.org/0000-0002-2532-471X)
- Rosely Maria Zancopé‐Oliveira (ORCID: https://orcid.org/0000-0001-7619-1921)
- Jefferson D. da Cruz (ORCID: https://orcid.org/0000-0002-0403-3198)
- Levi G. Cleare
- Jefferson Rocha de Andrade Silva (ORCID: https://orcid.org/0000-0003-2569-1306)
- Andréa Reis Bernardes‐Engemann (ORCID: https://orcid.org/0000-0002-4997-8734)
- Fernando Almeida‐Silva (ORCID: https://orcid.org/0000-0002-7378-1990)
- Rodrigo Almeida‐Paes (ORCID: https://orcid.org/0000-0002-6639-6058)
- Walter Sotto M. Fernandes Neto
Institutions
- Albert Einstein College of Medicine (US)
- Instituto Evandro Chagas (BR)
- Fundação Oswaldo Cruz (BR)
- Universidade Federal do Amazonas (BR)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2025-04-06
- DOI
- https://doi.org/10.3390/ph18040534
- Primary Topic
- Bee Products Chemical Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universidade Federal do Amazonas
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- National Institutes of Health